deucravacitinib
bms
['paisley', 'deucra']
promising phase 2 data on the efficacy and safety of deucravacitinib (oral allosteric tyk2 inhibitor) in patients with #sle (paisley); primary endpoint (sri4 at wk 32) was met and the drug was well tolerated. improvements in secondary endpoints also, incl lldas. #acr22 plenary 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders